Practical aspects of treatment discontinuation and adherence

Journal of Hypertension

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Parati, Gianfranco ^a,b,c   Bilo, Grzegorz ^a,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Centro Interuniversitario di Fisiologia Clinica e Ipertensione   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Adherence; Compliance; Discontinuation; Hypertension; Telmisartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE MONITORING; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; PATIENT COMPLIANCE; PATIENT MOBILITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYNCOPE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; ARTICLE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE;

EID: 69449096733     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000354515.36956.67     Document Type: Review

References (35)

1. Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
4. Stephenson J. Noncompliance may cause half of antihypertensive drug 'failures'. JAMA 1999; 282:313-314.
5. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician 1998; 57:1007-1014.
6. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
7. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183.
8. Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr Hypertens Rep 2007; 9:184-189.
9. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117.
10. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007; 15:257-263.
11. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005; 45:461-467.
12. Rubio A,Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992; 22:238-246.
13. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47:1039-1048.
14. Bloom BS. Daily regimen and compliance with treatment. BMJ 2001; 323:647.
15. Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol 2004; 11:e267-273.
16. Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. Med Gen Med 2007; 9:58.
17. Skelding PC, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, et al. Clinical and nonclinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization. J Clin Hypertens (Greenwich) 2006; 8:414-419.
18. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
19. Cummings KM, Kirscht JP, Binder LR, Godley AJ. Determinants of drug treatment maintenance among hypertensive persons in inner city Detroit. Public Health Rep 1982; 97:99-106.
20. Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: achieving blood pressure goals. J Clin Hypertens (Greenwich) 1999; 1:141-147.
21. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
22. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24:302-316.
23. Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy: the role of adverse effects and compliance. Blood Press 1998; 7:313-315.
24. Messerli FH, Bangalore S, Ram VS. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008; 359:426-427.
25. McMurray JJ. ACE inhibitors in cardiovascular disease: unbeatable? N Engl J Med 2008; 358:1615-1616.
26. Awad AG. Antipsychotic medications in schizophrenia: how satisfied are our patients? United Kingdom: Shire Hall International; 1999.
27. Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 2000; 160:481-490.
28. Luscher TF, Vetter H, Siegenthaler W, Vetter W. Compliance in hypertension: facts and concepts. J Hypertens Suppl 1985; 3:S3-S9.
29. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166:1842-1847.
30. Maronde RF, Chan LS, Larsen FJ, Strandberg LR, Laventurier MF, Sullivan SR. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989; 27:1159-1166.
31. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32:214-226.
32. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12:533-537.
33. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al., ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: asummary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26:1505-1526.
34. Detry JM, Block P, De Backer G, Degaute JP. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. Eur J Clin Pharmacol 1995; 47:477-481.
35. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719.